How effective is the targeted drug giritinib?

Giritinib targeted drug has remarkable efficacy, especially in the treatment of acute myeloid leukemia (AML) with FLT3 mutation.

Giritinib is the first oral drug targeting AML patients with FMS-like tyrosine kinase 3 (FLT3) mutations, and its efficacy has been fully verified in clinical trials. For example, in the pivotal ADMIRAL trial, giritinib significantly prolonged patients' event-free survival (EFS) compared with placebo, an important metric for assessing prognosis in patients with AML. Some patients achieved complete remission (CR) or partial remission (PR) after using giritinib, showing that the drug has a significant effect on improving the patient's condition.

Giritinib is particularly suitable for patients who carryFLT3 gene mutations, which is a common gene mutation in AML. For these patients, giritinib can provide targeted treatment, effectively control the disease and improve quality of life.

Although some side effects may occur during the use of giritinib, such as myalgia, arthralgia, elevated transaminases, etc., most reactions are mild to moderate and can be managed with appropriate dose adjustments or treatment strategies. In clinical trials, the safety of giritinib has been fully evaluated, and most patients can tolerate and benefit from it.

Compared with traditional chemotherapy drugs, giritinib has higher selectivity and specificity, and can accurately treatFLT3 mutations and reduce damage to normal cells. This makes giritinib more advantageous in terms of efficacy and safety.

The use of giritinib requires individualized treatment plan design based on the patient's specific conditions. Doctors will develop appropriate treatment strategies based on the patient's condition, physical condition, genetic mutation and other factors to ensure that the patient gets the best treatment effect.